Endocrine Abstracts

Objective: To determine the degree of control of hypercholesterolemia in a specific lipid unit.

Material and Methods: Retrospective study of patients followed in our unit over the past 16 years diagnosed with heterozygous familial hypercholesterolemia (HFH) or familial combined hyperlipidemia (FCH). Control criteria according to the following recommendations were compared: International Panel (2003), Nice (2008), NLA (2011), ESC / ESA 2011, Consensus ADA / American College of Cardiology Foundation.

Results: Data from 111 patients were analyzed: 66 with HFH and 45 with FCH.

Patients with HFH currently 91.4% are taking statins (rosuvastatin 36.2%, atorvastatin 31%) and 57.9% ezetimibe. The total initial and final cholesterol was: 280.9±67.1 vs 196.3±36.6 mg/dl, LDL-C: 194.1±71.2 vs 119.1±35.9 mg/dl, HDL-C: 55.4±12.9 vs. 59.4±16.5, non-HDL-C: 223±72.5 vs 134.7±34.9 mg/dl. The therapeutic goals for LDL were obtained in the following percentages: International Panel: 79.6%; Nice: 55.6%, NLA: 69.3% and ESC/ESA: 37.7%.

85.4% of FCH patients currently are taking statins (46.3% rosuvastatin, 22% fluvastatin), 65.9% fenofibrate, 29.3% omega 3 and 31.7% ezetimibe. The total initial and final cholesterol was: 282.5±63.8 vs 202.1±47.4 mg/dl, LDL-C: 155±41.5 vs 121.4±50.1 mg/dl, HDL-C: 35.5±12.1 vs 47.7±14.9, non-HDL C: 237.7±64.9 vs 151.9±46.9 mg/dl. According to the Consensus criteria ADA / American College of Cardiology Foundation therapeutic goals for LDL-C were achieved in 33.3% and for non-HDL C in 23.5%.

Conclusion: In patients with familial hypercholesterolemia, despite intensive treatment, therapeutic targets set by international guidelines are infrequently achieved.